Oftalmol Zh.2012;6:30-33.

Full text Pdf 



Pogoreliy D. N., Putienko A. A. Kovalchuk A. G

Odessa, Ukraine

112 patients (114 eyes) with proliferative diabetic retinopathy (PDRP) were studied the total area of the proliferative tissue in the zones of sclerotomies on an average in 2 and 6 months after vitrectomy. The area of proliferative tissue composed 2.09 (0.56) mm2 in the patients of the basic group — 82 eyes, with expressed hemophthalmia in 2 months after operation, while in the patients of the control group — 32 eyes with the transparent vitreal contents — 0.63 (0.49), the difference was statistically reliable (p= 0.0001). The regress of the proliferative tissue in the zone of sclerotomies in the patients of the basic group was noted in 6 months after treatment, based on the average value of 2.09 (0.56) mm2 to 0.58 (0.41) mm2, the differences were statistically reliable (p = 0.0001). In the control group it was 0.63 (0.49) mm2 to 0.52 (0.44) mm2.

Hemophthalmia after vitrectomy in the patients with PDRP is associated with development of the neovascular tissue in the zone of sclerotomies. The data of the state of the neovascular tissue for 6 months are evidence of the gradual stabilization of the proliferative process as a result of vitrectomy, which begins in a number of patients in the later periods after operation.



1.Носов С. В. Тактика лечения поздних поствитрэкто-мических гемофтальмов у больных сахарным диабетом // Офтальмохирургия. — 2011. — № 3. — С.53-56.

2.Тахчиди X. П., Носов С. В., Казайкин В. Н., Чаплин Г. В., Казанцев В. С. Прогнозирование постви-трэктомических гемофтальмов у больных сахарным диабетом методами распознавания образов / X. П. Тахчиди, С. В. Носов, В. Н. Казайкин и др. // Офтальмохирургический журнал. — № 2. — 2010. — С. 34- 38.

3.Entezari M. Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: a randomized clinical trial / M. Entezari, A. Ramezani, H. Ahmadieh // Graefes. Arch Clin Exp Ophthalmol. — 2010. — № 248. — P. 1-19.

4.Gbndbz K. Management of proliferative diabetic retinopathy / K. Gbndbz , S. J. Bakri // Compr. Ophthalmol Update. — 2007. — V.8. — № 5. — P.245- 256.

5.Rizzo S. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopa-thy (PDR) / S. Rizzo, F. Genovesi-Ebert, E. Di Bartolo et al. // Graefes. Arch Clin Exp Ophthalmol. — 2008. — № 246. — P.837-842.

6.Steel D. H. Entry Site Neovascularization and Vitreous Cavity Hemorrhage after Diabetic Vitrectomy The Predictive Value of Inner Sclerostomy Site Ultrasonography / D. H. Steel, A. Connor, M. S. Habib, // Br. J. Ophthalmol. — 2010. — № 94. — P.1219- 1225.

7.Steel D. H. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy/ D. H. Steel, M. S. Habib, S. Park // Ophthalmology. —   2008. — № 115. — p. 525- 532.

8.Yeh P. T. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study / P. T Yeh, C. M. Yang, C. H. Yang // Ophthalmology. — 2005. — № 112. — 2095- 2102.

9.Yorston D. Predictive clinical features and outcomes of vit-rectomy for proliferative diabetic retinopathy / D. Yorston, L. Wickham , S. Benson // Br. J. Ophthalmol. — 2008. — v. 9. — № 3. — p. 365- 368.

10.West J. F. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy / J. F. West, Z. J. Gregor // Br. J Ophthalmol. — 2000. — № 84. — P.822- 825.

11.Wu W. C. Management of postvitrectomy diabetic vitreous hemorrhage with volume homeostatic fluid-fluid exchanger / W. C. Wu, J. Y. Chen, Y. C. Chen // Graefes Arch Clin Exp Ophthalmol. — 2009. — V.247. — № 9. —P.1183-1189